Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles

Regionshospitalet Viborg, Skive384 enrolled

Overview

The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

384

Conditions

OHSS (Ovarian Hyperstimulation)

Interventions

Buserelin and PregnylDRUG

Subcutaneous injection 0.5 mg and 1500 IU

PregnylDRUG

Subcutaneous injection 5000 IU

Buserelin and PregnylDRUG

Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 39 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient complying with the conditions for IVF or ICSI treatment * Female age over 20 years and under 40 years * Normal regular cycle and patients with oligomenorrhea * BMI \> 18 and \< 35 * each patient contributes with one cycle only Exclusion Criteria: * Significant disturbances in the woman (diabetes, epilepsy, liver/renal/heart disease, metabolic disorder) * Patients with \> 25 follicles on the day of triggering ovulation

Locations (1)

The Fertility Clinic, Regional Hospital of Skive

Skive, Denmark

Outcomes

Primary Outcomes

Frequency of Moderate to Severe OHSS.

Time frame: From the date of triggering ovulation until 2 weeks after pregnancy test. group C and D. 12 days after pregnancy test

Secondary Outcomes

Pregnancy Rate

Time frame: from stimulation day 1 until last ultrasound scan 7 weeks after a positive pregnancy test

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.